News

U.Va. biolab seeks to catalyze region’s growth

Thomas Barker says his seed-stage startup wants to find “modern, modular, functional lab space” to allow the company he co-founded, Vasarya Therapeutics, to be “very efficient and optimal on our research enterprise.”

But good lab space is hard to come by in Charlottesville, and what exists is spread around, “so you don’t necessarily get the impact of having other startup and tech companies in your space being in close proximity,” adds Barker, who is also Vasarya’s chief scientific officer.

CvilleBioHub hopes to address those problems by creating CvilleBioLab, an accelerator where early-stage companies can spend a year or two performing research while also being mentored by business leaders and advisers who can help “de-risk” the startup process, including navigating issues like intellectual property protection, says Nikki Hastings, executive director and co-founder of the nonprofit. Founded in 2016, CvilleBioHub advocates for and works to build the area’s biotech community.

In March, the organization received a $100,000 GO Virginia grant to support planning for CvilleBioLab. While there’s no timeline for site selection, CvilleBioHub’s real estate partner, Rockville, Maryland-based Scheer Partners, is searching for an existing building to convert. “Ideally, we’d like 15,000 to 20,000 square feet, although we could get started with 5,000,” Hastings says.

Depending on the size, Hastings, the biotech track director at the University of Virginia’s McIntire School of Commerce, estimates spending around $3 million for infrastructure and equipment, with operating costs for staffing, maintenance, and overhead running between $500,000 and $1 million annually. Funding is still being determined, Hastings says.

The facility will include a wet lab and equipment including refrigerators, ultra-low-temperature freezers for DNA samples and other biological material, incubators, cell culture and DNA analysis tools, and basic lab equipment like microscopes.

The lab’s buildout is expected to take about a year. Companies will apply for a spot, with six to eight startups sharing the facility, though Hastings says CvilleBioHub will use part of the planning grant to “more definitively” determine programming during the summer. A lab director and entrepreneur advisory team will support occupants.

Charlottesville-area researchers who want to spin their work into a startup would benefit from having a formal incubator, says Renna Nouwairi, a Ph.D. candidate in bioanalytical chemistry at U.Va. “It would be a shame for our city and local economy to miss out on opportunities because a startup-friendly infrastructure is not in place.”

 

Learn more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation